4ABD Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$162.10 |
| 52 Week High | US$162.10 |
| 52 Week Low | US$125.90 |
| Beta | 0.56 |
| 1 Month Change | 0% |
| 3 Month Change | 1.50% |
| 1 Year Change | 20.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 11.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4ABD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.8% | 2.0% |
| 1Y | 20.9% | -23.3% | 4.5% |
Return vs Industry: 4ABD exceeded the UK Biotechs industry which returned -26.7% over the past year.
Return vs Market: 4ABD exceeded the UK Market which returned 3% over the past year.
Price Volatility
| 4ABD volatility | |
|---|---|
| 4ABD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 4ABD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4ABD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| 4ABD fundamental statistics | |
|---|---|
| Market cap | €266.90b |
| Earnings (TTM) | €5.53b |
| Revenue (TTM) | €50.53b |
48.3x
P/E Ratio5.3x
P/S RatioIs 4ABD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4ABD income statement (TTM) | |
|---|---|
| Revenue | US$54.40b |
| Cost of Revenue | US$16.85b |
| Gross Profit | US$37.56b |
| Other Expenses | US$31.60b |
| Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.37 |
| Gross Margin | 69.03% |
| Net Profit Margin | 10.94% |
| Debt/Equity Ratio | 924.1% |
How did 4ABD perform over the long term?
See historical performance and comparison